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Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD)
is a life-threatening complication of T-lymphocyte deplete allogeneic hematopoietic
stem cell transplantation (allo-HSCT). For patients with PTLD refractory to Rituximab,
donor lymphocyte infusion (DLI) is established as a successful option for salvage
therapy. However, although in vivo lymphocyte expansion has been correlated with
good clinical outcome following DLI, the specificity and functional characteristics of
EBV-specific T-cell responses remain poorly characterized. Here we describe two
patients with Rituximab-refractory PTLD complicating T-cell deplete allo-HSCT, both
of whom were successfully rescued with 1 × 106/Kg unselected stem cell donor-
derived DLI. Prospective analyses revealed that complete clinical and radiological
responses were associated with in vivo expansion of T and NK cells. Furthermore,
EBV MHC tetramer, and interferon gamma analyses revealed a marked increase in
EBV-specific T-cell frequency from 4 weeks after DLI. Reactivity was demonstrated
against a range of EBV latent and lytic antigens, including those detected in tumor
biopsy material. The immunodominant EBV-specific T cell response expanding in vivo
following infusion matched the dominant response present in the DLI preparations prior
to administration. Furthermore, differences in the repertoire of subdominant antigen-
specific T-cells were also detected, suggesting that antigen-encounter in vivo can shape
the immune response. These results demonstrate the value of prospectively studying in
vivo T-cell responses, by facilitating the identification of important specificities required
for clinical efficacy. Applying this approach on a larger scale promises to yield data which
may be essential for the optimization of future adoptive immunotherapeutic strategies
for PTLD.
Keywords: post-transplant lymphoproliferative disease, PTLD, Epstein-Barr virus, adoptive T-cell therapy, donor
lymphocyte infusion, T-cells, flow cytometry, tetramers
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INTRODUCTION
Post-transplant lymphoproliferative disease (PTLD) remains a
life-threatening complication of allogeneic hematopoietic stem
cell transplantation (allo-HSCT) (1, 2). In this setting almost
all cases arise from Epstein-Barr virus (EBV) transformed
donor-derived B lymphocytes. EBV is carried as a persistent
infection by more than 90% of the worldwide population (3).
In healthy individuals, potent EBV-specific CD8+ and CD4+
T-cell responses against a range of viral antigens exert control
over long-term infection (4). However, following allo-HSCT T-
cell compromise may permit the opportunistic accumulation of
infected B-cells, leading to PTLD. The reported incidence of
disease after allo-HSCT, ranging from < 1% to over 30% in
some series, is therefore heavily influenced by factors related
to host and graft T-cell suppression, in particular the use of T-
cell depleting agents such as anti-thymocyte globulin (ATG) and
Alemtuzumab (5).
Histologically, PTLD tumors exhibit a heterogeneous
spectrum of pathologies but they are most commonly
categorized as monomorphic diffuse large B-cell lymphomas
(DLBCL) or polymorphic B-cell proliferations (6). In these,
EBV genomes are detectable as a growth transforming infection,
expressing a well-characterized set of latent virus gene products,
comprising 6 EBV nuclear antigens (EBNA-1,-2,-3A,3B,-3C,
and -LP), 3 latent membrane proteins (LMP-1,-2A,-2B) and
BHRF1 (3). Several studies have also documented virus lytic
cycle activity in a small fraction of tumor cells, a process
driven by expression of the viral transcription factor BZLF1
(7, 8). However, some tumors, often those arising later after
transplant, are less reliant on the EBV transforming genes and
express a more limited range of viral genes, with concurrent
cellular mutations.
Rituximab, a B lymphocyte-specific anti-CD20 monoclonal
antibody, has significantly improved PTLD-related mortality
following allo-HSCT (9), particularly when used as pre-emptive
treatment in patients with raised circulating EBV DNA (10–13).
Despite this, a proportion of patients fail to respond to, or relapse
following, Rituximab therapy and are at high risk of mortality
(9, 14). Whilst cytotoxic chemotherapy may be efficacious
for Rituximab-refractory PTLD in the setting of solid organ
transplantation, poor outcomes are reported after allo-HSCT,
which is probably related to toxicity (14, 15). Considerably better
clinical responses have been achieved using cellular therapies.
Thus, transplant donor-derived unselected donor lymphocyte
infusions (DLI), which contain EBV-specific T-cells whenever the
donor is EBV-seropositive, have been used as successful salvage
therapy for established PTLD, with response rates of around
70% (16–19). However, this approach is limited by the risk of
alloreactive T-cell responses, which may result in potentially
life-threatening graft-vs. -host disease (GvHD). Alternatively,
EBV-specific cytotoxic T-cell (EBV CTL) infusions, prepared
by in vitro stimulation of donor or third-party lymphocytes,
avoid this complication. These have been used effectively both
as prophylaxis and in the treatment of established disease,
resulting in response rates similar to those achievedwithDLI and,
importantly, without evidence of alloreactivity (11, 20–22).
Unfortunately, EBV CTLs are still not universally available,
due in part to the laborious and costly nature of their production
(2). Novel approaches, including ex vivo selection of virus-
specific T-cells (23–25) or genetically engineered T-cells (26),
are seeking to address this issue. Clearly, the success of these
selective adoptive cellular approaches will crucially depend on
the targeting of appropriate antigens. It is notable therefore,
that whilst in vivo expansion of adoptively transferred DLI
and EBV CTLs has been correlated with successful clinical
outcome (18), the dominant antigenic specificities present within
polyclonal third party EBV CTLs prior to infusion do not
correlate with clinical response (27), and thus the in vivo T-
cell responses required to deliver clinical response are as yet
poorly defined.
In the present study we propose that prospective analysis
of the T-cell responses expanding in vivo after adoptive cell
therapy might better shed light on the specificities required
for effective therapeutic responses. As such we describe 2 cases
of Rituximab-refractory EBV-positive PTLD arising after allo-
HSCT successfully rescued using unselected DLI. We present
the first detailed characterization of EBV epitope–specific T-cell
responses both within the DLI, and within the in vivo expanded
T-cells following infusion. We demonstrate non-uniform in
vivo expansion of functional epitope-specific CD8+ and CD4+
T-cells recognizing viral antigens expressed within the PTLD
tumor cells.
MATERIALS AND METHODS
Patients
Both patients underwent allo-HSCT at Nottingham University
Hospitals NHS Trust (NUH), Nottingham, UK, and were treated
in accordance with institutionally approved protocols. The
research was conducted with Research Ethics Committee and
NHS Research and Development approval (12/WM/0147, West
Midlands – Coventry and Warwickshire) and participants gave
written informed consent in accordance with the Declaration of
Helsinki. Patients undergoing allo-HSCT at NUH are routinely
monitored with whole blood EBV qPCR testing weekly for at least
6 months post-transplant. Pre-emptive treatment comprising up
to 4 infusions of Rituximab 375 mg/m2 is delivered to those
exceeding an institutionally defined threshold of 10,000 EBV
genomes/ml. PTLD was diagnosed in accordance with published
criteria (28).
Analysis of Lymphocyte Subsets
Peripheral blood mononuclear cells (PBMCs) were isolated
using density centrifugation. PBMCs and aliquots of donor
lymphocytes were analyzed immediately or cryopreserved.
Thawed PBMCs were stained in MACS buffer on ice for
30min using pre-determined concentrations of the following
antibodies: CD14-Pacific Blue (M5E2), TCRα/β-AF488 (IP26),
CD56-PE (HCD56), CD8-PerCP-Cy5.5 (SK1), and CD45-AF700
(HI30) from Biolegend; CD19-PE-Cy7 (HIB19), CD4-APC
(SK3), and CD3-APC-eFluor780 (UCHT1) from eBioscience.
After washing in MACS buffer, and addition of Sytox
Blue (Invitrogen) for dead cell discrimination, cells were
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acquired on an LSRII (BD) flow cytometer (Beckman Coulter).
Doublets, CD14+ monocytes and dead cells were excluded
before a minimum of 30,000 CD45+ lymphocyte events
were recorded. Data were analyzed using FacsDIVA software
version 6.1.3 (BD). Lymphocyte counts, from routine clinical
analysis of whole blood, were used to calculate lymphocyte
subset frequency.
EBV Epitope-Specific T-Cell Assays
Interferon-gamma (IFN-γ) release Elispot assays were performed
on PBMC or donor lymphocytes stimulated at 2 × 105
cells/well overnight using CD8+ and CD4+ T-cell EBV
epitope peptides (Tables S1, S2) at a final concentration
of 5µg/ml, as previously described (29). All peptides were
analyzed in duplicate or triplicate wells, and DMSO was
used as a negative control. For MHC class I tetramer
analysis, thawed PBMCs were exposed for 15min at 37◦C
to pre-titrated volumes of APC-conjugated HLA A∗0201
tetramers for EBV epitopes YVLDHLIVV (BRLF1 aa 109-
117), GLCTLVAML (BMLF1 aa 280-288), and CLGGLLTMV
(LMP2 aa 426-434) (30). The cells were subsequently washed
in PBS, stained with LIVE/DEAD fixable violet dead cell
stain (Life Technologies), and surface stained using pre-
determined concentrations of CD3-AmCyan (SK7) and CD8-
PE (RPA-T8) antibodies (BD Biosciences). After washing,
the cells were acquired on an LSRII flow cytometer. Data
were processed using FlowJo software version 7.6.5 (Tree
Star). Absolute numbers of tetramer-specific T-cells were
calculated from lymphocyte subset frequencies determined as
described above.
Immunohistochemistry and Epstein-Barr
Virus-Encoded Small RNAs (EBERs) in situ
Hybridization
For immunohistochemistry, sections from paraffin-embedded
biopsy material were dewaxed in Histoclear for 10min,
rehydrated and quenched in 0.3% H2O2 for 15min. The
slides were subsequently boiled in citrate buffer pH6.0 for
20min for antigen retrieval (40min for BZLF1 staining). After
blocking with Casein, the slides were incubated overnight
at 4◦C with primary antibodies diluted in PBS with 0.5%
Tween20 against: EBNA1 IH4 (1:1,000), EBNA2 PE2 (1:2),
LMP1 CS1-4 (Dako; 1:25), LMP2A 15F9 (Santa Cruz; 1:100),
BZLF1 BZ.1 (neat), and gp350 72A1 (1:1,000). After 3 washes
in PBS/Tween20, slides were incubated for 30min at room
temperature with the secondary antibody Dako Real EnVision
HRP Rabbit/Mouse, or Dako Rabbit anti-Rat-HRP (1:100)
for LMP2a staining. After three washes with PBS/Tween20,
100 µl diaminobenzidine (Dako) was applied to each slide
for visualization, counter-staining with Meyers Hematoxylin.
EBER in situ hybridization (EBER ISH) was performed with
a Leica automated Bond system, using an EBER probe in
combination with an anti-fluorescein antibody and Bond
Polymer Refine Detection (Leica Biosystems), according to
manufacturer’s instructions.
TABLE 1 | Patient characteristics.
Patient A Patient B
Age at transplant, years 51 62
Sex Female Female
Diagnosis LPL AML
FIRST TRANSPLANT
Donor Unrelated Sibling
Conditioning Flu BEAM Flu Mel
T-cell depletion Alemtuzumab Alemtuzumab
SECOND TRANSPLANT
Donor Unrelated Sibling
Conditioning Flu-Cy FLAMSA-Bu
T-cell depletion ATG ATG
EBV Serology
Recipient + +
Donor + +
HLA Type
A 02, 32 01, 24
B 44, 49 07, 14
C 05, 07 07, 08
DRB1 01, 15 07, 15
DQB1 05, 06 02, 06
LPL, lymphoplasmacytic lymphoma; AML, acute myeloid leukemia; Flu BEAM,
Fludarabine, Carmustine, Etoposide, Cytarabine, Melphalan; Flu Mel, Fludarabine,
Melphalan; Flu Cy, Fludarabine, Cyclophosphamide; FLAMSA-Bu, Fludarabine,
Cytarabine, Amsacrine, ATG, Busulfan; ATG, antithymocyte globulin; EBV, Epstein-Barr
virus; HLA, human leukocyte antigen; +, positive.
RESULTS
Patient Presentation and Treatment
This study used clinical data and samples collected from 2
patients who underwent treatment with DLI for Rituximab-
refractory PTLD arising after allo-HSCT. Baseline and transplant
characteristics for the patients are summarized in Table 1.
Patient A underwent allo-HSCT for lymphoplasmacytic
lymphoma in partial remission using Fludarabine, BEAM,
and Alemtuzumab preparative conditioning, with an HLA-
matched unrelated donor with a single HLA-A antigen mismatch
(HLA A26 for A32). Due to graft failure, a second transplant
from the same donor was performed using Fludarabine,
Cyclophosphamide and ATG conditioning. EBV qPCR testing of
whole blood revealed low-level EBV DNAemia on day 71 post
second transplant, with a virus load of 760 copies/ml (Figure 1A,
left). Despite weaning Cyclosporin, this subsequently rose to
high-level EBV DNAemia (28,150 copies/ml) by day 99. The
patient was treated with Rituximab 375 mg/m2, administered
weekly to a total of 4 infusions, resulting in a decline in EBV load
to a nadir of 5470 copies/ml on day 127. However, 7 days after
the fourth infusion, there was recrudescence of EBV DNAemia
which progressed on further testing. This was accompanied
by severe oropharyngeal inflammation and ulceration causing
absolute dysphagia and airway compromise which progressed
despite empirical antimicrobial therapy and systemic steroids.
Imaging including Positron emission tomography-computed
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tomography (PET-CT) revealed active disease principally
involving Waldeyer’s Ring and confluent, full-length esophageal
involvement (Figure 1B, left). An oropharyngeal biopsy
confirmed monomorphic PTLD of DLBCL subtype, which was
positive for EBV by EBER in situ hybridization but negative for
CD20 immunohistochemistry consistent with prior Rituximab
exposure (Figure 1C) (31).
Patient B underwent allo-HSCT for AML in first complete
remission, with Fludarabine, Melphalan, and Alemtuzumab
preparative conditioning, using peripheral blood stem cells
(PBSC) from a fully HLA-antigen matched sibling donor. A
second allograft from the same donor was performed ∼18
months later (day 0) following relapse of primary disease, with
FLAMSA (ATG-containing) and Busulfan conditioning. EBV
monitoring revealed a viral load of 9,810 copies/ml on day 63
(post second transplant) which progressed to 370,000 copies/ml
on day 71 (Figure 1A, right). Consequently, pre-emptive therapy
with Rituximab 375 mg/m2 was administered to a total of
4 weekly infusions, resulting in reduction of EBV load to a
nadir of 8,625 copies/ml after the third infusion. However, 6
days following the fourth infusion there was recrudescence of
EBV DNAemia with a virus load of 20,760 copies/ml which
subsequently increased. This was associated with general malaise
and B symptoms, and PET-CT revealed active disease involving
the nasopharynx, spleen and multiple lymph nodes (Figure 1B,
right). In the absence of an amenable biopsy site, a diagnosis of
probable PTLD was made (28).
The patients were subsequently treated with single infusions
of 1 × 106/Kg unselected donor lymphocytes derived from their
EBV-immune stem cell donors. Neither received chemotherapy.
In both, a rapid and sustained response to DLI was observed,
comprising reduction of EBV load to undetectable levels,
resolution of symptoms (Figure 1A), and complete metabolic
response defined by PET-CT (Figure 1B). Except for stage 1
skin GvHD in Patient A, administration of DLI was tolerated
without complication. Patient A remains well after more than 3
years of follow-up. Patient B remained in remission from PTLD
but died from relapsed AML around 8 months following their
second transplant.
Expansion of Lymphocyte Subsets
Following DLI
Blood samples were collected prospectively following
administration of DLI to monitor in vivo immune responses.
Inspection of total lymphocyte counts revealed a similar pattern
of lymphocyte expansion following DLI infusion in both patients
(Figure 1D). Thus, marked lymphopenia was noted prior to
infusion, with counts of only 300 cells/µl in both patients
(normal range 1,000 – 4,000 cells/µl). Although these were
unchanged at 2 weeks following infusion, by 4 weeks there were
sharp increases to 2,500 cells/µl and 1,100 cells/µl for Patients A
and B, respectively. Thereafter, the lymphocyte counts decreased
to near baseline frequencies by 13 weeks in Patient A, and by
8 weeks in Patient B (although there was a further increase at
the 10 week timepoint in the latter). In order to characterize
lymphocyte subsets, PBMCs were analyzed using a multicolor
flow cytometry panel to enumerate CD3+ T-cells (and CD8+
and CD4+ subsets), CD56+ natural killer (NK)-cells and
CD19+ B-cells (Figure 1D). This revealed a predominance of
NK-cells, and few T-cells, in the pre-DLI and 2 week timepoints.
However, by 4 weeks both the CD8+ and CD4+ T-cell subsets
underwent marked expansion, accompanied by a similar increase
in NK-cells. Despite prior Rituximab therapy, CD19+ B-cells
constituted 1.0% of lymphocytes at 2 weeks post-DLI-infusion
in Patient A but reduced to 0.1% by the 4 week timepoint, and
remained at trace levels at 13 weeks (maximum 0.3%) before
increasing to 20.1% at 1 year. In Patient B, B-cells made up 1.6%
of lymphocytes pre-DLI, falling to 0.6% at 2 weeks post-DLI and
remained at trace levels at 10 weeks (maximum 0.2%). Overall,
these data suggest that DLI-derived CD8+ and CD4+ T-cells
and NK-cells all underwent in vivo expansion following infusion,
co-incident with reduction in residual circulating B-cells.
Characterization of EBV Epitope-Specific
T-Cell Responses
Whilst previous studies have demonstrated global expansion
of EBV-specific T-cells following administration of DLI, the
antigenic specificities of these cells, which likely represent
therapeutically important responses, have not been characterized
(18, 32). To enumerate EBV epitope-specific T-cell responses
for study patients, PBMCs were stimulated overnight with
appropriate EBV peptides (detailed in Tables S1, S2) and
responding CD8+ and CD4+ T-cells were quantified using IFN-
γ release Elispot assay.
Initially, we tested aliquots of the donor lymphocytes
administered to each patient (Figure 2A). In both donors, EBV-
specific CD8+, and CD4+ T-cell responses to a range of
EBV antigens were observed, noting prominent responses to
immunodominant epitopes, as typically seen in healthy EBV
seropositive individuals (33–35). DLI given to Patient A (left
panel) exhibited strong responses to the CD8+ T-cell epitopes
EEN (EBNA3C), KEH (EBNA3C), CLG (LMP2), and YVL
(BRLF1), whilst the DLI for Patient B (right panel) showed
responses against the CD8+ T-cell peptides TYS (EBNA3B) and
RPP (EBNA3A), and the CD4+ T-cell peptide PRS (EBNA2).
In contrast, analysis of patient PBMCs collected prior to
DLI infusion showed responses undetectable above background
(Figure 2B). Responses remained poor at 2 weeks after DLI.
However, by 4 weeks there was a marked increase in EBV-specific
T-cell frequency. For each case, emergent immunodominant T-
cell responses matched those present at the highest frequency
in the corresponding DLI samples. However, it was also
notable that subdominant responses included some, but not
all, of the epitope specificities identified in the DLI. Thus,
in Patient A (left panel) the CD8+ response was dominated
by reactivity against the CD8+ YVL (BRLF1) peptide, with
weaker responses to the LMP2 peptides FLY, CLG, and LLW,
and very low/undetectable responses to EEN (EBNA3C), GLC
(BMLF1), and FLD (BALF4). In Patient B (right panel) the RPP
(EBNA3A) peptide and the CD8+ peptide pool (a composite of
lytic antigen peptides) elicited the strongest responses, whereas
responses to RYS (EBNA3A) and TYS (EBNA3B) were almost
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FIGURE 1 | Patient A (Left) and B (Right) Investigations. (A) EBV loads in whole blood, measured by EBV qPCR, and shown as EBV copies/ml whole blood. Day 0
represents the time of second transplant. The dotted line represents the 500 copies/ml threshold of sensitivity for the EBV qPCR assay, below which values are
arbitrarily shown as 250 copies/ml. R indicates infusion of Rituximab 375 mg/m2; DLI, donor lymphocyte infusion of 1.0 × 106/Kg. (B) Positron emission tomography
images taken pre and post-DLI infusion (Day 0). Patient A had active disease principally located in the oropharynx and esophagus. Patient B had active disease in the
oropharynx, spleen and lymph nodes. (C) Analysis of formalin-fixed, paraffin-embedded diagnosis biopsy tissue sections from Patient A showing widespread positivity
for EBERs on in situ hybridization but predominantly negative immunohistochemistry for CD20. Images are 40X magnified. (D) Kinetics of total lymphocyte (joined
dots) and main lymphocyte subset counts (stacked columns), pre and post-DLI infusion. NT indicates not tested. Expansion of T-cell and NK-cell subsets was
observed at 4 weeks after DLI in both patients.
undetectable. Epitope-specific CD4+ T-cells were also detected
in both patients, most evidently against the pool of CD4+
latent epitope peptides in Patient A, and the MVF (EBNA1)
peptide and CD4+ peptide pool (a composite of lytic antigens
plus EBNA3C peptides) in Patient B. Interestingly, CD4+ T-
cell responses may have preceded those of CD8+ T-cells in
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FIGURE 2 | Prospective analysis of EBV epitope-specific T-cell responses. Aliquots of the infused DLI (A) or PBMCs from serially collected samples from patients A
and B (B) were stimulated overnight with selected panels of CD8+ and CD4+ epitope peptides of relevant HLA class I and class II restriction (Tables S1, S2) before
enumeration of responding cells using IFN-γ Elispot. Results shown are the mean spot forming units (SFUs) per 2 × 105 cells from duplicate or triplicate wells +/– SD.
(C) Immunohistochemistry analysis of Formalin-fixed, paraffin-embedded diagnosis biopsy sections from Patient A, showing strong positivity for latent EBV antigens
EBNA1, EBNA2, LMP1, and LMP2 and the lytic EBV antigen BZLF1 but absence of the late lytic cycle antigen gp350. Images are 60X magnified.
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Patient A at week 2. The responses persisted in both patients,
most notably Patient A in whom EBV-specific T-cells were
detectable at both 52 weeks and 2 years following DLI (data
not shown).
Expression of EBV T-Cell Target Antigens
in PTLD Tissue
Importantly, we also investigated the presence of the
corresponding viral antigens within PTLD tumor tissue. As
such, sections from the PTLD biopsy available from Patient
A were subjected to immunohistochemistry for a range of
EBV proteins (Figure 2C). This showed expression of EBNA-1,
EBNA-2, LMP-1, and LMP-2 latent proteins, consistent with a
growth transforming Latency III pattern of virus gene expression.
Importantly, these included several proteins recognized by the
T-cells expanding in vivo post-DLI (Figures 2, 3). Notably,
the EBV lytic cycle antigen BZLF1, expression of which is
responsible for initiating the virus replication program, was
also readily detected in a small proportion of cells. However,
late lytic cycle glycoprotein 350 (gp350), which contributes
to the virus envelope and is one of the final proteins to be
expressed from the EBV genome, was absent. Control gp350
staining of cells within the EBV-positive cell line Akata is shown
in Figure S1.
EBV-Specific T Cell Expansion Following
DLI
As IFN-γ release may underestimate the total frequency of
antigen-specific T-cells (36), we subsequently sought to quantify
EBV-specific T-cells by flow cytometry, using MHC class I
tetramers. Reagents were available for the HLA A∗02 restricted
EBV latent epitope CLG (LMP2) and the EBV lytic epitopes YVL
(BRLF1) and GLC (BMLF1). These were used to analyze PBMCs
from HLA A∗02-positive Patient A, to determine responding T-
cells as a proportion of circulating CD8+ T-cells (Figure 3A).
Responses to all 3 tetramers were undetectable at 2 weeks
following DLI, consistent with a general absence of CD8+ T-
cells at this timepoint (Figure 1D). However, by 4 weeks after
DLI, responses to YVL (BRLF1), and GLC (BMLF1) tetramers
were markedly increased, comprising 5.7 and 1.5% of circulating
CD8+ T-cells, respectively (Figure 3A). These responses were
maximal at this timepoint and remained elevated at 8 weeks. The
response to GLC (BMLF1) was less marked but also increased
to a maximum of 1.0% of CD8+ T-cells at 8 weeks. Notably,
12 months after infusion of DLI the frequencies of MHC class I
tetramer-specific cells within the CD8+ T-cell subset had fallen
to levels typically found in a healthy EBV-seropositive adult
(37). The frequency (cells/µl) of EBV tetramer-specific CD8+
T-cells was subsequently calculated (Figure 3B), revealing the
full magnitude and kinetics of these responses. Importantly,
this demonstrated the close alignment of EBV epitope-specific
CD8+ T-cell expansion with resolution of viral DNAemia,
particularly for the immunodominant EBV lytic peptide epitope
YVL (BRLF1).
DISCUSSION
Whilst pre-emptive Rituximab constitutes an effective strategy
to reduce PTLD-associated mortality after allo-HSCT, it
nevertheless remains suboptimal. Treatment itself may confer
an increased risk of opportunistic infection (38), and around
10% of patients treated pre-emptively develop established
disease with Rituximab refractoriness (28). Given disappointing
outcomes observed with cytotoxic chemotherapy, cellular
therapies offer the best chance of rescue. However, effective
responses to DLI or EBV CTLs are also not universal, and
∼30% of patients fail treatment (18). Understanding the viral
and immunological variables that influence outcome is crucial
for the optimization of future adoptive immunotherapeutic
approaches. In the current study the potential value of
performing detailed immune characterization following
administration of cellular therapy is exemplified with 2 cases of
Rituximab-refractory PTLD successfully rescued with DLI. Here
the administered cells contain the full repertoire of donor EBV
immunity, providing an opportunity to investigate the antigen
specificities of in vivo responding cells, unbiased by prior in
vitro selection.
Both study patients received single doses of 1 × 106/kg
unselected transplant donor-derived lymphocytes from
their EBV-immune stem cell donors. These infusions
resulted in complete clinical response, comprising sustained
resolution of EBV DNAemia and remission of radiological
abnormalities. Notably, this was accompanied by marked
expansion in circulating lymphocytes, with peak frequencies
observed within 4 weeks of DLI. The lymphocyte expansions
contained both CD8+ and CD4+ T-cells, consistent with
previous reports that successful treatment of established
PTLD correlates with restoration of T-cell numbers (18).
Interestingly, we also observed simultaneous increases in
CD3-CD56+ NK-cell numbers, potentially through stimulation
by NKG2D, and/or DNAM-1 ligands upregulated on EBV-
infected cells undergoing lytic replication (39, 40). Notably,
in vitro studies have shown that this lymphocyte subset,
some of which are primed for rapid IFN-γ production
(41), may play a role in limiting B-cell transformation
by EBV (42, 43). Whilst their contribution to the clinical
responses seen against established PTLD following DLI
is yet to be determined, increased NK frequencies have
been reported in patients with controlled low-level EBV
reactivation (44).
To dissect the CD8+ and CD4+ T-cell responses expanding
in vivo after DLI, we performed detailed analysis of antigen
specificities present both in the infused cell preparations, and
in patient PBMCs collected pre- and post-DLI. Previous studies,
undertaken in similarly treated patients, have been limited
to estimations of global EBV-specific T-cell numbers using
LCL or peptide pool stimulation followed by various in vitro
readout assays (18, 45, 46). Whilst such methods provide a
good measure of total EBV-specific responses, individual epitope
specificities are not captured. In the current study, we instead
used panels of patient HLA-relevant EBV epitope peptides to
determine the frequency of individual epitope-specific responses
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FIGURE 3 | MHC I tetramer analysis of EBV epitope-specific CD8+ T-cell responses following DLI. PBMCs from HLA A*02-positive Patient A were stained with HLA
A*02 tetramers containing YVL (BRLF1), CLG (LMP2), and GLC (BMLF1) epitope peptides. (A) Depicted results show lymphocytes co-stained for CD8+ and tetramer,
compared to a no tetramer control (left column). Cell populations within the boxes indicate the percentage of tetramer-positive cells within the CD8+ T-cell population.
(B) Comparison of response in whole blood viral load with the absolute frequency of EBV-specific T-cells recognizing YVL (BRLF1), CLG (LMP2), and GLC (BMLF1) in
cells/µl over time. Vertical dotted lines represent the time of DLI.
by IFN-γ Elispot. This approach has previously been used to
track the kinetics of infused peptide-selected T-cells of known
specificity (23). In both patients, expanded T-cells contained
immunodominant responses identical to those present in the
DLI prior to infusion, i.e., YVL (BRLF1) for Patient A, and
RPP (EBNA3A) for Patient B, and subdominant responses
to a range of other CD8+ and CD4+ peptides. Crucially,
detection of IFN-γ release in these ex vivo assays demonstrates
that the expanded T-cells are able to function in response
to their cognate antigen. Furthermore, we were also able to
quantify absolute numbers of EBV epitope-specific CD8 T-cells
for Patient A, whose HLA I type was amenable to analysis
with HLA-A∗02 restricted EBV peptide/MHC I tetramers.
Unmistakably, the peak frequencies of tetramer positive cells
in the blood coincided with the dynamics of total lymphocyte
expansion, in line with reports of clinical responses occurring
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concurrently with expansion of LCL-reactive cells (18, 32).
At this time, > 8% of all circulating CD8+ T-cells were
specific for the available MHC I tetramers. Given that the
observed responses represent only 3 epitopes from the entire
virus genome, restricted through a single HLA I allele, it is
likely that the majority of the expanded CD8+ T-cells are in
fact EBV-specific.
In both cases, whilst immunodominant T-cell reactivity
was preserved between DLI and patient, we observed notable
differences in the repertoire of subdominant responses present
in the DLI vs. those appearing in vivo after infusion.
Thus, for Patient A the FLY (LMP2) peptide elicited the
second largest response following infusion, whilst stronger
responses in the DLI-EEN (EBNA3C) and FLD (BALF4)-
were almost undetectable. Similarly, in Patient B reactivity
against the CD8+ peptide pool, containing a number of
lytic antigen-derived peptides, was more prominent 4 weeks
post-infusion than in the DLI, whereas the TYS response
of the DLI was undetectable after infusion. These differing
patterns indicate non-uniform expansion of EBV epitope-
specific T-cells present in the DLI following administration, and
suggest that antigen encounter in vivo is shaping the observed
responses. Furthermore, they may explain why attempts to
simply correlate the dominant antigen specificities present in
heterogeneous in vitro-stimulated therapeutic cell preparations
with clinical outcome, have thus far proven unsuccessful
(27, 46).
Immunohistochemistry on biopsy material from Patient A
demonstrated expression of several proteins associated with the
viral latency III program. Importantly, this included proteins that
were targets of the expanded CD8+T-cell response. Additionally,
we detected unequivocal expression of the immediate early (IE)
lytic cycle protein BZLF1. This transcription factor is the key
initiator of EBV lytic cycle, and drives sequential expression of
over 60 viral proteins involved in virus replication (3). However,
despite widespread BZLF1 expression in the biopsy, we could
not detect expression of the late (L) virion structural protein
gp350. Such observations accord with earlier evidence that lytic
cycle may not always progress to late stages in PTLD tumors
(7, 8). In this regard, abortive lytic cycle has been suggested
as a possible pathogenic mechanism, whereby IE and E viral
protein expression might enhance tumourigenesis (47) without
completing replication, which would otherwise eliminate the host
cell (48). Interestingly, although we were only able to analyze a
limited number of epitopes, this pattern was reflected in the T-
cell specificities expanded in vivo. Thus, the immunodominant
reactivity in the blood of Patient A following DLI was against
the IE epitope YVL (BRLF1), whereas L epitope FLD (BALF4)
responses were absent during the time of PTLD resolution.
These data indicate that tumor antigen expression drives non-
uniform T-cell expansion, and suggest that T-cells active against
latent and early lytic antigens may be more therapeutically
important than L antigen-specific responses in the setting
of PTLD.
Collectively, this study demonstrates the importance of
studying the antigen specificity of T-cell responses that expand
in vivo following DLI. The application of this approach to
a larger cohort of patients, with comparative analysis of
individuals according to clinical response may deliver essential
advances in the development of adoptive cell therapy for PTLD.
Furthermore, extending the analysis of T-cell responses after
DLI to include other viruses, such as Cytomegalovirus and
Adenovirus will afford the opportunity to confirm that T-cell
expansion is indeed driven by specific viral antigens. Of course,
the study of virus-specific responses in recipients of DLI will
not in itself inform the risk of potentially life-threatening acute
GvHD, which is the principal limitation of DLI. However,
it is notable that strategies, which do not require the prior
selection of particular EBV antigen-specific T-cells by ex vivo
purification and/or culture, might be used to mitigate this risk.
For example, prior depletion of naïve T-cells from the DLI
preparation has the potential to reduce the risk of GvHD, without
compromising the range of EBV antigens targeted or EBV-
specific cytotoxicity (49).
In summary, we report the successful treatment of Rituximab-
refractory PTLD arising after allo-HSCT using DLI. Moreover,
we have undertaken detailed analyses of virus-specific immune
response developing in vivo following adoptive transfer. Disease
resolution was found to coincide with marked expansion of
lymphocytes, including functional EBV epitope-specific CD8+
and CD4+ T-cells exhibiting reactivity against a range of latent
and IE lytic antigens, which were also expressed in tumor
biopsy material. Importantly, although immunodominant T cell
reactivity was preserved between DLI and patients following
infusion, expansion of other DLI-derived antigen-specific T-
cells was not uniform. This indicates that presentation of
viral epitopes from the tumor may drive the in vivo immune
response. These findings have important implications for the
optimization of future adoptive immunotherapeutic strategies,
including those involving ex vivo selected T-cells (23, 24) or
genetically engineered T-cells. Thus, similar analyses of post-DLI
expanded T-cells from larger series of patients, including non-
responders, promise to facilitate the identification of essential
T-cell responses required for therapeutic efficacy.
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